NCT05910398View on ClinicalTrials.gov

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

488

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

April 30, 2030

Study Completion Date

August 31, 2030

Conditions
Breast Cancer Invasive
Interventions
DRUG

pyrotinib

an irreversible anti-HER2 tyrosine kinase inhibitor

Trial Locations (1)

200127

RECRUITING

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER